Volume 29, Issue 4, 2020
DOI: 10.24205/03276716.2020.888
Therapeutic Effects of Mesalazine Enteric-Coated Tablets Combined with Low Molecular Heparin on Ulcerative Colitis and Influence on The Hypercoagulable State
Abstract
Objective: To evaluate the therapeutic effects of mesalazine enteric-coated tablets combined with low molecular heparin on ulcerative colitis and the influence on the hypercoagulable state.
Methods: A total of 100 patients suffering from ulcerative colitis and hospitalized in Department of Gastroenterology of our hospital from January 2017 to December 2019 were collected and divided into two groups (n=50) using a random number table. Control group was administered with mesalazine enteric-coated tablets and observation group was administered with mesalazine enteric-coated tablets combined with low molecular heparin. The overall response rate, symptom score, inflammatory factors in the serum, blood rheology indices, quality-of-life score, and incidence rate of adverse reactions were compared between the two groups.
Results: The overall response rate was 96.00% in observation group, higher than that in control group (82.00%) (P<0.05). The symptom scores involving abdominal pain, diarrhea and hematochezia after treatment were lower than those before treatment in the two groups (P<0.05), whereas they were lower in observation group than those in control group after treatment (P<0.05). C-reactive protein (CRP), interleukin-6 (IL-6) and procalcitonin (PCT) decreased significantly after treatment compared with those before treatment in the two groups, and observation group had lower CRP, IL-6 and PCT than control group after treatment (P<0.05). In comparison with those before treatment, there were significant decreases in hematocrit (HCT), erythrocyte sedimentation rate (ESR) and plasma viscosity (PV), after treatment in the two groups, and they were also lower in observation group than those in control group after treatment (P<0.05). The quality-of-life score after treatment was higher than that before treatment in the two groups (P<0.05), and the above score after treatment in observation group was higher than that in control group (P<0.05). No significant difference was found in the incidence rate of adverse reactions between the two groups, which was 6.00% in observation group and 4.00% in control group (P>0.05).
Conclusion: Mesalazine enteric-coated tablets combined with low molecular heparin in the treatment of ulcerative colitis can effectively alleviate relevant symptoms, reduce inflammatory response and hypercoagulable states and help improve the quality of life, with obvious efficacy, few adverse reactions and high safety.
Keywords
gastroenterology; ulcerative colitis; mesalazine enteric-coated tablet; low molecular heparin